Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer Inc. (PFE): A Buy Despite Negative News

Page 2 of 2

Bottom line

The company stock has depreciated approximately 1% on negative news of Zithromax but it should bounce back once again. Pfizer has a number of interesting candidates which have recently received FDA nod and some still in the trial phase. Any updates or news on PD-0332991, Eliquis and Xeljanz can be a catalyst for the stock price. Despite recent appreciations the company is still trading 7% below mean sell side target price of $30 and offers a healthy 3.4% dividend yield as well. Pfizer Inc. (NYSE:PFE) remains one of the best placed stocks in the healthcare stock and is a long term buy.

The article A Buy Despite Negative News originally appeared on Fool.com and is written by Mohsin Saeed.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Page 2 of 2